Alto Neuroscience, Inc.
NYSE:ANRO · New York Stock Exchange
+$0.40 today
Vol 0.19M · Avg 0.34M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NYSE:ANRO · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$74.3M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-2.48, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 -100.0% | $210.0K | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $661.0K +31.7% | $502.0K | $0 -100.0% | $342.0K +135.9% | $145.0K | $725.6M | $804.0M | $882.4M |
| Gross Profit | -$661.0K -31.7% | -$502.0K | $0 +100.0% | -$342.0K -626.2% | $65.0K | $8.9B | $7.6B | $6.2B |
| Gross Margin | — | — | — | — | 31.0% | 9.8% | 28.9% | 38.3% |
| Research & Development | $45.6M -2.9% | $47.0M +55.1% | $30.3M +27.9% | $23.7M +183.0% | $8.4M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $20.7M -4.0% | $21.6M +187.5% | $7.5M +45.6% | $5.2M +37.6% | $3.8M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $65.7M -3.5% | $68.1M +80.1% | $37.8M +31.1% | $28.9M +138.0% | $12.1M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $661.0K +31.7% | $502.0K +34.6% | $373.0K +9.1% | $342.0K +135.9% | $145.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$60.1M +3.5% | -$62.3M -80.3% | -$34.6M -26.3% | -$27.4M -202.7% | -$9.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | — | — | — | — | -4305.7% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$66.4M +3.3% | -$68.6M -81.5% | -$37.8M -29.5% | -$29.2M -142.1% | -$12.1M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | — | — | — | — | -5741.0% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.6M -25.4% | $8.9M +276.8% | $2.3M +1960.5% | $114.0K +5600.0% | $2.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $2.5M +279.6% | -$1.4M -200.4% | $1.4M | $0 | $0 | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $3.1M -56.5% | $7.2M +377.3% | $1.5M +1.5% | $1.5M -48.3% | $2.9M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$63.2M -2.9% | -$61.4M -69.2% | -$36.3M -31.0% | -$27.7M -201.6% | -$9.2M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | — | — | — | — | -4374.8% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 | $0 | $1.3B | -$1.6B | $745.2M |
| Net Income | -$63.2M -2.9% | -$61.4M -69.2% | -$36.3M -31.0% | -$27.7M -201.6% | -$9.2M | $4.9B | $4.8B | $4.7B |
| Net Margin | — | — | — | — | -4374.8% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$2 +12.4% | -$3 -85.2% | -$1 -25.0% | -$1 -200.0% | -$0 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$2 +12.4% | -$3 -85.2% | -$1 -25.0% | -$1 -200.0% | -$0 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $28.9M +17.3% | $24.6M -8.5% | $26.9M +5.1% | $25.6M +0.0% | $25.6M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $28.9M +17.3% | $24.6M -8.5% | $26.9M +5.1% | $25.6M +0.0% | $25.6M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Alpha Tau Medical Ltd.
NASDAQ:DRTS
$868.65M
Contineum Therapeutics, Inc. Class A Common Stock
NASDAQ:CTNM
$441.91M
DBV Technologies S.A.
NASDAQ:DBVT
$381.67M
Amarin Corporation plc
NASDAQ:AMRN
$335.06M
Silence Therapeutics plc
NASDAQ:SLN
$324.02M
Cellectis S.A.
NASDAQ:CLLS
$316.31M
Larimar Therapeutics, Inc.
NASDAQ:LRMR
$299.95M
AC Immune S.A.
NASDAQ:ACIU
$239.68M
Korro Bio, Inc.
NASDAQ:KRRO
$126.12M
Aldeyra Therapeutics, Inc.
NASDAQ:ALDX
$116.72M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does ANRO generate?
Alto Neuroscience, Inc. (ANRO) reported $0.00 of revenue in fiscal 2025.
Is ANRO profitable?
Alto Neuroscience, Inc. (ANRO) reported -$63,238,000.00 of net income.
Explore More
Continue the stock analysis
Jump to another research area for this company.